Unified protocol for the transdiagnostic treatment of borderline personality disorder

The applicability and efficacy of Transdiagnostic cognitive behavior therapy on reducing signs and symptoms of Borderline Personality Disorder with co-occuring emotional disorders

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015110524899N1

Enrollment

Registered

2016-11-10

Start date

2015-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Borderline personality disorder. Condition 2: Depression. Condition 3: Anxiety. Emotionally unstable personality disorder Moderate depressive episode Other anxiety disorders

Interventions

Patients will participate in 16-20 weekly transdiagnostic cognitive behavior treatment sessions..

Behavior

Patients will participate in 16-20 weekly transdiagnostic cognitive behavior treatment sessions.

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria are: a) age above 18, b) Borderline Personality disorder (BPD) based on psychiatric diagnostic interview by psychiatrist and SCID-II by clinical psychologist, and c) another emotional disorder as a comorbid disorder based on psychiatric diagnostic interview by psychiatrist and SCID-I by clinical psychologist. Exclusion criteria are: a) presence of diagnostic criteria for psychotic disorder/bipolar disorder/ drug abuse or dependency in the time of research, b) risk of imminently suicidal attempt.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Diagnostic Recovery. Timepoint: pre-post treatment. Method of measurement: SCHID-II.;Emotion Regulation. Timepoint: pre-post treatment & after each module. Method of measurement: Difficulties in Emotion Regulation Scale(DERS).;Alexithymia. Timepoint: pre-post treatment. Method of measurement: Toronto Alexithymia Scale (TAS-20).;General function. Timepoint: pre-post treatment. Method of measurement: Work and Social Adjustment Scale (WSAS).;Depression. Timepoint: pre-post treatment & after each module. Method of measurement: Depression Anxiety Stress Scale -42.;Anxiety. Timepoint: pre-post treatment & after each module. Method of measurement: Depression Anxiety Stress Scale -42.;Affect Intensity. Timepoint: pre-post treatment. Method of measurement: Affect Intensity Measure (AIM).;Affective Lability. Timepoint: pre-post treatment. Method of measurement: Affective Lability Scale (ALS).	—

Measure

Time frame

Diagnostic Recovery. Timepoint: pre-post treatment. Method of measurement: SCHID-II.;Emotion Regulation. Timepoint: pre-post treatment & after each module. Method of measurement: Difficulties in Emotion Regulation Scale(DERS).;Alexithymia. Timepoint: pre-post treatment. Method of measurement: Toronto Alexithymia Scale (TAS-20).;General function. Timepoint: pre-post treatment. Method of measurement: Work and Social Adjustment Scale (WSAS).;Depression. Timepoint: pre-post treatment & after each module. Method of measurement: Depression Anxiety Stress Scale -42.;Anxiety. Timepoint: pre-post treatment & after each module. Method of measurement: Depression Anxiety Stress Scale -42.;Affect Intensity. Timepoint: pre-post treatment. Method of measurement: Affect Intensity Measure (AIM).;Affective Lability. Timepoint: pre-post treatment. Method of measurement: Affective Lability Scale (ALS).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarzaneh Mohamadi

Shahid Beheshti University of Medical Sciences

farzanehmohammadi86@gmail.com+98 903 812 9162

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026